HC Wainwright Increases Cadrenal Therapeutics (NASDAQ:CVKD) Price Target to $32.00

Cadrenal Therapeutics (NASDAQ:CVKD) had its target price boosted by analysts at HC Wainwright from $3.00 to $32.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 80.49% from the stock’s previous close.

Cadrenal Therapeutics Stock Performance

NASDAQ:CVKD opened at $17.73 on Monday. Cadrenal Therapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $32.55. The stock’s 50 day moving average is $13.09. The stock has a market capitalization of $18.94 million, a P/E ratio of -2.68 and a beta of 1.52.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.